Participant Age Range
30 years and younger
“Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)”
The benefit of chemotherapy will be tested in pediatric HCC and correlated with histologic and biologic heterogeneity. Outcomes of the arms proposed in this protocol will significantly redefine and clarify both the standard of care in treating pediatric HB and HCC around the world as well as our biologic understanding of these diseases.